

**Committee for Medicinal Products for Human Use (CHMP)
European Medicines Agency (EMA)
Domenico Scarlattilaan 6
1083 HS Amsterdam,
The Netherlands**

Letter Date: Sep 9th, 2021
Letter No.: CGP/EMA-090921-004
Procedure No.: EMEA/H/C/005543/0000

Dear CHMP Chairman, Rapporteurs and Scientific Administrators,

We would like to inform you that at this point of time, CinnaGen Co. Unipessoal Lda has taken the decision to withdraw the application for marketing authorization of:

Teriparatide 20 micrograms/80 microliters solution - EMEA/H/C/005543/0000

Which was intended to be used for treatment of Osteoporosis.

This withdrawal is based on the following reason:

CinnaGen Co. Unipessoal Lda has decided to discontinue this application since the objections raised cannot be addressed within the available timeframe.

We reserve the right to make further submissions in the future.

We agree for this letter to be published on the EMA website.

Yours Sincerely,



CinnaGen Co. Unipessoal Lda

Rua Alfândega, 78, 3rd Floor Funchal, Ilha Da Madeira 9000-059, Portugal